Skip to content
BioSupply Trends Quarterly logo
  • About Us
  • About Us
Subscribe
  • News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
    • Technology
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
    • Podcast
  • Issues
    • Current Issue
    • Past Issues
  • News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
    • Technology
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
    • Podcast
  • Issues
    • Current Issue
    • Past Issues
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
    • Technology
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
    • Podcast
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
    • Technology
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
    • Podcast
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
BioSupply Trends Quarterly logo

New Assay to Accurately Measure FXI Levels During IVIG Therapy

GC Biopharma has developed a proprietary enzyme-linked immunoassay (ELISA) that effectively mitigates heterophilic antibody interference to precisely measure factor XI (FXI) levels.

Novel Flu Vaccine Offers Broad Protection Against Multiple Flu Viruses

A potentially effective mucosal vaccine platform has been developed to encourage broad, protective immunity against multiple influenza virus infections.

Flu Vaccine Even with Infection Reduces Risk of Heart and Stroke

A new study shows that influenza vaccination may help protect against heart attack and stroke even when it does not prevent people from getting the flu.

High-Dose Flu Vaccine Significantly Lowers Risk of Developing Alzheimer’s

Researchers have found that adults 65 and older who received a high-dose influenza vaccine had a significantly lower risk of developing Alzheimer’s disease compared to those who received the standard dose.

FDA Approves Gene Therapy for Rare Immune Disorder

FDA has approved Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe leukocyte adhesion deficiency type I.

IVIG Effective in Treating Infants with HDFN

A recent study has found intravenous immune globulin (IVIG) therapy in infants with hemolytic disease of the fetus and newborn (HDFN) found that it could be beneficial.

Airborne Spread of Flu Is Reduced by Targeting Two Flu Proteins

A new study demonstrates a way to stop the influenza virus from leaping from one host to the next while continuing to keep the virus from replicating inside the host.

AREXVY RSV Vaccine Approved for Expanded Age Indication

The U.S. Food and Drug Administration has expanded the approved age indication of AREXVY to adults aged 18 to 49 years at increased risk for lower respiratory tract disease caused by RSV.

IVIG Plus IVMP Does Not Increase Remission Rates in CIDP Patients

According to a recent study, adding intravenous methylprednisolone to intravenous immune globulin induction therapy does not significantly increase remission rates among patients with chronic inflammatory demyelinating polyradiculoneuropathy.

New Skin Patch More Accurately Monitors Immune Conditions

Researchers have developed a bandage-like microneedle patch that samples key cells often missed in routine blood samples and biopsies without the need for taking blood or surgical biopsies.

← Previous
Next →
BioSupply Trends Quarterly logo
FFF Enterprises logo
  • Current Issue
  • Past Issues
  • Resources
  • Current Issue
  • Past Issues
  • Resources
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
Facebook-f Linkedin-in

FFF Enterprises.com | Privacy Statement | Terms of Use | California Consumer Privacy Act (CCPA) Opt-Out Icon

FFF Enterprises.com
Privacy Statement
Terms of Use
California Consumer Privacy Act (CCPA) Opt-Out Icon

©2024 FFF Enterprises, Inc. All Rights Reserved. Property of FFF Enterprises, Inc.

The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.